nach oben

International Urology and Nephrology

Erschienen in:

01.09.2010 | Nephrology - Review

Bone mineral density in patients on maintenance dialysis

verfasst von: Csaba Ambrus, Adrienn Marton, Zsofia Klara Nemeth, Istvan Mucsi

Erschienen in: International Urology and Nephrology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Disorders of bone and mineral metabolism affect almost all patients with advanced chronic kidney disease (CKD). High prevalence of decreased bone mineral density has been reported in this population; however, the role and diagnostic utility of bone density measurements are not well established. The incidence of bone fractures is high in patients with ESRD, but the association between fractures and bone density is not obvious. A recent meta-analysis suggested that decreased density at the radius might be associated with higher overall fracture risk. Changes in bone mineral density reflect several underlying pathological processes, such as vitamin D deficiency, estrogen deficiency and changes in bone turnover. The response of bone to these factors and processes is not uniform: it can vary in different compartments of the same bone or in different bones of the skeleton. Therefore, it is important to differentiate between the various types of bone. This may be possible by proper selection of the measurement site or using methods such as quantitative bone computed tomography. Previous studies used different methods and measured bone mineral density at diverse sites of the skeleton, which makes the comparison of their results very difficult. The association between changes in bone mineral metabolism and cardiovascular mortality is well known in ESRD patients. Studies also suggest that low bone density itself might be an indicator for high risk of cardiovascular events and poor overall outcome in this population. Some of the risk factors of low bone mineral density, such as vitamin D or estrogen deficiency, are potentially modifiable. Further studies are needed to elucidate if interventions modifying these risk factors will have an impact on clinical outcomes. In this review, we discuss the options for and problems of assessment of bone density and summarize the literature about factors associated with low bone density and its link to clinical outcomes in patients on maintenance dialysis.

Alem AM, Sherrard DJ, Gillen DL et al (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399PubMedCrossRef

Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366PubMedCrossRef

Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121PubMedCrossRef

Mittalhenkle A, Gillen DL, Stehman-Breen CO (2004) Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44:672–679PubMedCrossRef

Ketteler M, Gross ML, Ritz E (2005) Calcification and cardiovascular problems in renal failure. Kidney Int 94(Suppl):S120–S127CrossRef

Matsubara K, Suliman ME, Qureshi AR et al (2008) Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality. Blood Purif 26:284–290PubMedCrossRef

Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953PubMedCrossRef

Roux C, Dougados M (2000) Quantitative ultrasound in postmenopausal osteoporosis. Curr Opin Rheumatol 12:336–345PubMedCrossRef

Hans D, Fuerst T, Uffmann M (1996) Bone density and quality measurement using ultrasound. Curr Opin Rheumatol 8:370–375PubMedCrossRef

10.

Gluer CC (1997) Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res 12:1280–1288

11.

Bauer DC, Gluer CC, Cauley JA et al (1997) Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 157:629–634

12.

Peretz A, Penaloza A, Mesquita M et al (2000) Quantitative ultrasound and dual X-ray absorptiometry measurements of the calcaneus in patients on maintenance hemodialysis. Bone 27:287–292PubMedCrossRef

13.

Pluskiewicz W, Adamczyk P, Drozdzowska B et al (2003) Skeletal status in children and adolescents with chronic renal failure before onset of dialysis or on dialysis. Osteoporos Int 14:283–288PubMedCrossRef

14.

Przedlacki J, Pluskiewicz W, Wieliczko M et al (1999) Quantitative ultrasound of phalanges and dual-energy X-ray absorptiometry of forearm and hand in patients with end-stage renal failure treated with dialysis. Osteoporos Int 10:1–6PubMedCrossRef

15.

Tribl B, Vogelsang H, Pohanka E et al (1998) Broadband ultrasound attenuation of the calcaneus. A tool for assessing bone status in patients with chronic renal failure. Acta Radiol 39:637–641PubMedCrossRef

16.

Duan Y, De Luca V, Seeman E (1999) Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab 84:718–722PubMedCrossRef

17.

Jamal SA, Chase C, Goh YI et al (2002) Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 39:843–849PubMedCrossRef

18.

Chen Q, Kaji H, Iu MF et al (2003) Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88:4655–4658PubMedCrossRef

19.

Russo CR, Taccetti G, Caneva P et al (1998) Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int 8:443–448PubMedCrossRef

20.

Jamal SA, Gilbert J, Gordon C et al (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543–548PubMedCrossRef

21.

Ott SM (2008) Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 3(Suppl 3):S151–156PubMedCrossRef

22.

Cunningham J, Sprague SM, Cannata-Andia J et al (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571PubMedCrossRef

23.

Dolgos S, Hartmann A, Bonsnes S et al (2008) Determinants of bone mass in end-stage renal failure patients at the time of kidney transplantation. Clin Transplant 22:462–468PubMedCrossRef

24.

Taal MW, Masud T, Green D et al (1999) Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 14:1922–1928PubMedCrossRef

25.

Yamaguchi T, Kanno E, Tsubota J et al (1996) Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19:549–555PubMedCrossRef

26.

Ersoy FF, Passadakis SP, Tam P et al (2006) Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 24:79–86PubMedCrossRef

27.

Krieger NS, Frick KK, Bushinsky DA (2004) Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13:423–436PubMedCrossRef

28.

Mehrotra R, Kopple JD, Wolfson M (2003) Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int 64(Suppl):S13–25CrossRef

29.

Eleftheriadis T, Kartsios C, Antoniadi G et al (2008) The impact of chronic inflammation on bone turnover in hemodialysis patients. Ren Fail 30:431–437PubMedCrossRef

30.

Elder GJ, Mackun K (2006) 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 21:1778–1784PubMedCrossRef

31.

Negri AL, Barone R, Lombas C et al (2006) Evaluation of cortical bone by peripheral quantitative computed tomography in continuous ambulatory peritoneal dialysis patients. Hemodial Int 10:351–355PubMedCrossRef

32.

Urena P, Bernard-Poenaru O, Ostertag A et al (2003) Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18:2325–2331PubMedCrossRef

33.

Joffe P, Podenphant J, Heaf JG (1989) Bone histology in CAPD patients: a comparison with hemodialysis and conservatively treated chronic uremics. Adv Perit Dial 5:171–176PubMed

34.

Stehman-Breen CO, Sherrard D, Walker A et al (1999) Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 33:941–946PubMedCrossRef

35.

Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38:323–329PubMedCrossRef

36.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRef

37.

Del Valle E, Negri AL, Aguirre C et al (2007) Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 11:315–321PubMedCrossRef

38.

Mehrotra R, Kermah D, Budoff M et al (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3:1144–1151PubMedCrossRef

39.

Taskapan H, Ersoy FF, Passadakis PS et al (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 66:247–255PubMed

40.

Sahin G, Kirli I, Sirmagul B et al (2009) Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients. Int Urol Nephrol 41:989–996CrossRefPubMed

41.

Shany S, Rapoport J, Goligorsky M et al (1984) Losses of 1, 25- and 24, 25-dihydroxycholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal dialysis. Nephron 36:111–113PubMedCrossRef

42.

Aloni Y, Shany S, Chaimovitz C (1983) Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. Miner Electrolyte Metab 9:82–86PubMed

43.

Bischoff-Ferrari HA, Dietrich T, Orav EJ et al (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639PubMedCrossRef

44.

Tomida K, Hamano T, Mikami S et al (2009) Serum 25-hydroxyvitamin D as an independent determinant of 1–84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 44:678–683PubMedCrossRef

45.

Fournier A, Bordier P, Gueris J et al (1979) Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 15:196–204PubMedCrossRef

46.

Ghazali A, Fardellone P, Pruna A et al (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55:2169–2177PubMedCrossRef

47.

Mucsi I, Almasi C, Deak G et al (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64:288–294PubMed

48.

Coen G, Mantella D, Manni M et al (2005) 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68:1840–1848PubMedCrossRef

49.

Weisinger JR, Gonzalez L, Alvarez H et al (2000) Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 58:331–335PubMedCrossRef

50.

Holley JL, Schmidt RJ, Bender FH et al (1997) Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 29:685–690PubMedCrossRef

51.

Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S et al (1999) The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 14:1238–1243PubMedCrossRef

52.

Sherrard DJ, Hercz G, Pei Y et al (1993) The spectrum of bone disease in end-stage renal failure–an evolving disorder. Kidney Int 43:436–442PubMedCrossRef

53.

Hutchison AJ, Whitehouse RW, Boulton HF et al (1993) Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071–1077PubMedCrossRef

54.

Schober HC, Han ZH, Foldes AJ et al (1998) Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 9:1225–1233PubMed

55.

Haas M, Leko-Mohr Z, Roschger P et al (2002) Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39:580–586PubMedCrossRef

56.

Barreto FC, Barreto DV, Moyses RM et al (2006) Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 69:1852–1857PubMedCrossRef

57.

Wang M, Hercz G, Sherrard DJ et al (1995) Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836–844PubMedCrossRef

58.

Gerakis A, Hutchison AJ, Apostolou T et al (1996) Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 11:2430–2438PubMed

59.

Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150PubMedCrossRef

60.

Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J et al (2004) Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 19:1587–1593PubMedCrossRef

61.

Monier-Faugere MC, Malluche HH (1996) Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11(Suppl 3):111–120PubMed

62.

Lacativa PG, de Mendonca LM, de Mattos Patricio Filho PJ et al (2005) Risk factors for decreased total body and regional bone mineral density in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Densitom 8:352–361PubMedCrossRef

63.

Hercz G, Pei Y, Greenwood C et al (1993) Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function. Kidney Int 44:860–866PubMedCrossRef

64.

Pei Y, Hercz G, Greenwood C et al (1993) Renal osteodystrophy in diabetic patients. Kidney Int 44:159–164PubMedCrossRef

65.

Rix M, Andreassen H, Eskildsen P et al (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093PubMedCrossRef

66.

Inaba M, Okuno S, Nagasue K et al (2001) Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am J Kidney Dis 38:S139–S142PubMedCrossRef

67.

Inaba M, Okuno S, Kumeda Y et al (2005) Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 76:256–260PubMedCrossRef

68.

Mucsi I, Hercz G (1999) Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 317:405–409PubMedCrossRef

69.

Wada T, Nakashima T, Hiroshi N et al (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25PubMedCrossRef

70.

Li Y, Toraldo G, Li A et al (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848PubMedCrossRef

71.

McClung MR (2006) Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4:28–33PubMedCrossRef

72.

Mesquita M, Wittersheim E, Demulder A et al (2005) Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 21:181–184PubMed

73.

Shaarawy M, Fathy SA, Mehany NL et al (2007) Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med 45:1498–1503PubMedCrossRef

74.

Fahrleitner-Pammer A, Dobnig H, Dimai HP et al (2009) The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. Clin Nephrol 71:652–659PubMed

75.

Doumouchtsis K, Perrea D, Doumouchtsis S et al (2009) Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial 13:49–55PubMedCrossRef

76.

Speer G, Fekete BC, El Hadj Othmane T et al (2008) Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 23:3256–3262PubMedCrossRef

77.

Kovesdy CP, Kalantar-Zadeh K (2008) Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40:427–440PubMedCrossRef

78.

Wang H, Yoshiko Y, Yamamoto R et al (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948PubMedCrossRef

79.

Sitara D, Razzaque MS, St-Arnaud R et al (2006) Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169:2161–2170PubMedCrossRef

80.

Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123PubMedCrossRef

81.

Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774PubMedCrossRef

82.

Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51PubMedCrossRef

83.

Imanishi Y, Inaba M, Nakatsuka K et al (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946PubMedCrossRef

84.

Torres PU, Prie D, Molina-Bletry V et al (2007) Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 71:730–737PubMedCrossRef

85.

Kojima F, Uchida K, Ogawa T et al (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067–1074PubMedCrossRef

86.

Johnson DW, Herzig KA, Purdie DM et al (2000) Is obesity a favorable prognostic factor in peritoneal dialysis patients? Perit Dial Int 20:715–721PubMed

87.

Mottet JJ, Horber FF, Casez JP et al (1996) Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis. J Bone Miner Res 11:96–104PubMedCrossRef

88.

Hampson G, Vaja S, Evans C et al (2002) Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephron 91:94–102PubMedCrossRef

89.

Pasadakis P, Thodis E, Manavis J et al (1995) The identification of bone mineral density in CAPD in comparison with HD patients. Adv Perit Dial 11:247–253PubMed

90.

Couttenye MM, D’Haese PC, Deng JT et al (1997) High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144–2150PubMedCrossRef

91.

Haris A, Sherrard DJ, Hercz G (2006) Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 70:931–937PubMedCrossRef

92.

Kurz P, Tsobanelis T, Roth P et al (1995) Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 44:255–261PubMed

93.

Negri AL, Barone R, Quiroga MA et al (2004) Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 24:163–168PubMed

94.

Stehman-Breen CO, Sherrard DJ, Alem AM et al (2000) Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200–2205PubMedCrossRef

95.

Danese MD, Kim J, Doan QV et al (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149–156PubMedCrossRef

96.

White BL, Fisher WD, Laurin CA (1987) Rate of mortality for elderly patients after fracture of the hip in the 1980’s. J Bone Joint Surg Am 69:1335–1340PubMed

97.

Atsumi K, Kushida K, Yamazaki K et al (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287–293PubMedCrossRef

98.

Jamal SA, Hayden JA, Beyene J (2007) Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 49:674–681PubMedCrossRef

99.

Spasovski GB (2007) Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 39:1209–1216PubMedCrossRef

100.

London GM, Marty C, Marchais SJ et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943–1951PubMedCrossRef

101.

Tanko LB, Christiansen C, Cox DA et al (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912–1920PubMedCrossRef

102.

Adragao T, Herberth J, Monier-Faugere MC et al (2009) Low bone volume–a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 4:450–455PubMedCrossRef

103.

Toussaint ND, Lau KK, Strauss BJ et al (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593PubMedCrossRef

104.

Browner WS, Seeley DG, Vogt TM et al (1991) Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 338:355–358PubMedCrossRef

105.

von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273–278CrossRef

106.

Taal MW, Roe S, Masud T et al (2003) Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63:1116–1120PubMedCrossRef

107.

Jean G, Terrat JC, Vanel T et al (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23:3670–3676PubMedCrossRef

108.

Baskin E, Ozen S, Karcaaltincaba M et al (2004) Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism. Int Urol Nephrol 36:113–118PubMedCrossRef

109.

Wang SX, Li H (2008) Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients. Chin Med J (Engl) 121:1280–1284

110.

Bekker PJ, Holloway DL, Rasmussen AS et al (2005) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res 20:2275–2282PubMedCrossRef

111.

Wetmore JB, Benet LZ, Kleinstuck D et al (2005) Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) 10:393–399CrossRef

112.

Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233PubMedCrossRef

113.

Fraser WD, Logue FC, Christie JP et al (1998) Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Osteoporos Int 8:121–126PubMedCrossRef

114.

Onyia JE, Miles RR, Yang X et al (2000) In vivo demonstration that human parathyroid hormone 1–38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863–871PubMedCrossRef

115.

Finkelstein JS, Klibanski A, Arnold AL et al (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): a randomized controlled trial. JAMA 280:1067–1073PubMedCrossRef

116.

Glover SJ, Eastell R, McCloskey EV et al (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45:1053–1058PubMedCrossRef

117.

Matsumoto T, Hagino H, Shiraki M et al (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437PubMedCrossRef

118.

Lien YH, Silva AL, Whittman D (2005) Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20:1232–1237PubMedCrossRef

119.

Zayour D, Daouk M, Medawar W et al (2004) Predictors of bone mineral density in patients on hemodialysis. Transplant Proc 36:1297–1301PubMedCrossRef

Titel: Bone mineral density in patients on maintenance dialysis
verfasst von: Csaba Ambrus
Adrienn Marton
Zsofia Klara Nemeth
Istvan Mucsi
Publikationsdatum: 01.09.2010
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 3/2010
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-009-9666-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Does Arkadia contribute to TGF-β1-induced IgA expression through up-regulation of Smad signaling in IgA nephropathy?

Epithelial–mesenchymal transition to be or not to be? Is the answer yes and no at the same time?

Expression of P311, a transforming growth factor beta latency-associated protein-binding protein, in human kidneys with IgA nephropathy

Bladder cancer incidence and mortality rates compared to ecologic factors among states in America

Postnatal assessment of growth, nutrition, and urinary tract infections of infants with antenatally detected hydronephrosis